XSHE
300289
Market cap490mUSD
Oct 09, Last price
6.12CNY
1D
1.49%
1Q
10.47%
Jan 2017
-50.84%
IPO
-1.92%
Name
Beijing Leadman Biochemistry Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beijing Leadman Biochemistry Co.,Ltd. is a prominent entity within the People's Republic of China, specializing in the entire lifecycle – from research and development to manufacturing and distribution – of advanced in vitro diagnostic (IVD) solutions. Its product portfolio encompasses a comprehensive range of biochemical raw materials. This includes critical components like enzymes, coenzymes, antibodies, various buffers, enzyme substrates, culture media, staining reagents, and amino acids. These essential ingredients serve a diverse array of sectors, notably biotechnology, clinical diagnostics, pharmaceutical development, and chemical manufacturing. Beyond raw materials, Leadman also provides specialized biochemistry diagnostic and complementary reagents. Furthermore, the company supplies a sophisticated selection of medical instrumentation. This lineup features the EnigmaML, an automated molecular testing platform designed for both clinical laboratories and various point-of-care settings like clinics and pharmacies. Another key offering is the DiaSys InnovaStar, a compact automated POCT analyzer that delivers laboratory-grade diagnostic accuracy. Customers also benefit from the DiaSys Respons, a versatile random access benchtop analyzer; the CI1000 automatic chemiluminescence immunoassay analyzers; and the IDS-isys, an instrument engineered to boost operational performance and efficiency. Established in 1997, Beijing Leadman Biochemistry maintains its corporate headquarters in Beijing, China.
Key people
President · since 2018
Yang Cheng
Finance Director · since 2019
Lihua Zhang
Deputy General Manager, Secretary of the Board · since 2019
Lin Lin
Chairman of the Board · since 2019
Zhenbin Qian
Director · since 2019
Qian Sun
Director
Independent Director
Ruiqi Wang
Independent Director · since 2012
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||